MedTrace Logo

OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma

NCT04931368 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 331

Last updated 2026-03-18

No results posted yet for this study

Summary

This phase III study investigates if a de-escalated induction treatment in newly diagnosed primary CNS lymphoma is superior to the standard MATRix protocol in terms of event free survival.

Conditions

Interventions

DRUG

Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix

De-escalated induction treatment with R/HD-MTX and two courses of MATRix

DRUG

Control intervention: four courses of MATRix

Patients receive four courses of MATRix as induction treatment.

Sponsors & Collaborators

  • German Federal Ministry of Education and Research

    collaborator OTHER_GOV

  • University Hospital Freiburg

    collaborator OTHER

  • Klinikum Stuttgart

    lead OTHER

Principal Investigators

  • Gerald Illerhaus, Prof · Klinikum Stuttgart

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-28
Primary Completion
2028-06-30
Completion
2028-11-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04931368 on ClinicalTrials.gov